Search results for "Benzene"
showing 10 items of 1701 documents
Molecular mechanisms of sorafenib action in liver cancer cells.
2012
Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of advanced hepatocellular carcinoma (HCC). However, as the clinical application of sorafenib evolves, there is increasing interest in defining the mechanisms underlying its anti-tumor activity. Considering that this specific inhibitor could target unexpected molecules depending on the biologic context, a precise understanding of its mechanism of action could be critical to maximize its treatment efficacy, while minimizing adverse effects. Two human HCC cell lines (HepG2 and Huh7), carrying different biological and genetic characteristics, were used in this study to examine the intracellular events leading …
A systems biology perspective on cholangiocellular carcinoma development: focus on MAPK-signaling and the extracellular environment.
2008
Background/Aims Multiple genes have been implicated in cholangiocellular carcinoma (CCC) development. However, the overall neoplastic risk is likely associated with a much lower number of critical physiological pathways. Methods To investigate this hypothesis, we extracted all published genetic associations for the development of CCC from PubMed (genetic association studies, but also studies associating genes and CCC in general, i.e. functional studies in cell lines, genetic studies in humans, knockout mice etc.) and integrated CCC microarray data. Results We demonstrated the MAPK pathway was consistently enriched in CCC. Comparing our data to genetic associations in HCC often successfully …
Sorafenib in advanced hepatocellular carcinoma
2008
none 25 BACKGROUND: No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma. METHODS: In this multicenter, phase 3, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced hepatocellular carcinoma who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or placebo. Primary outcomes were overall survival and the time to symptomatic progression. Seconda…
Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy
2011
A multicenter randomized controlled trial established sorafenib as a standard of care for patients with advanced hepatocellular carcinoma (HCC). Because the study was prematurely interrupted due to survival benefits in the sorafenib arm, we conducted an observational study to adequately assess risks and benefits of this regimen in field practice. Starting in 2008, all clinically compensated patients with advanced HCC and those with an intermediate HCC who were unfit or failed to respond to ablative therapies were consecutively evaluated in six liver centers in Italy, for tolerability as well as radiologic and survival response to 800-mg/d sorafenib therapy. Treatment was down-dosed or inter…
Multimodal approaches to the treatment of hepatocellular carcinoma.
2008
The prevalence of hepatocellular carcinoma in Europe and the US is increasing and is currently the leading cause of death in patients with cirrhosis. Surveillance programs for patients with cirrhosis aim to detect tumors at an early stage, when the greatest therapeutic benefits can be achieved. Curative treatments for early-stage tumors include liver transplantation, resection and percutaneous ablation. Transarterial chemoembolization (TACE) and sorafenib can improve survival for patients with intermediate and advanced tumors, respectively. In clinical practice, combination therapies are often used, despite limited evidence to support this approach from randomized controlled trials. Combina…
CCDC 820755: Experimental Crystal Structure Determination
2011
Related Article: F.Riobe, F.Piron, C.Rethore, A.M.Madalan, C.J.Gomez-Garcia, J.Lacour, J.D.Wallis, N.Avarvari|2011|New J.Chem.|35|2279|doi:10.1039/c1nj20310j
CCDC 194090: Experimental Crystal Structure Determination
2003
Related Article: M.Poyatos, E.Mas-Marza, J.A.Mata, M.Sanau, E.Peris|2003|Eur.J.Inorg.Chem.||1215|doi:10.1002/ejic.200390157
CCDC 802648: Experimental Crystal Structure Determination
2011
Related Article: R.D.Costa, D.Tordera, E.Orti, H.J.Bolink, J.Schonle, S.Graber, C.E.Housecroft, E.C.Constable, J.A.Zampese|2011|J.Mater.Chem.|21|16108|doi:10.1039/c1jm12607e
CCDC 800788: Experimental Crystal Structure Determination
2011
Related Article: Hyui Sul Lee, M.Niemeyer|2011|Inorg.Chim.Acta|374|163|doi:10.1016/j.ica.2011.01.079
CCDC 1469012: Experimental Crystal Structure Determination
2016
Related Article: Filip Topić and Kari Rissanen|2016|J.Am.Chem.Soc.|138|6610|doi:10.1021/jacs.6b02854